News

Spectrum (SPPI) has acquired 100% rights to RenaZorb (RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications. The acquisition

The European Commission (EC) has approved Afinitor (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), whose disease progressed on or after treatment with

NPS Pharmaceuticals has reported net income of $2.6 million or $0.05 per diluted share, for the second quarter of 2009, compared to net income of $1.2 million or

Orexo’s partner, ProStrakan has submitted to FDA the New Drug Application (NDA) for Abstral, for the treatment of breakthrough cancer pain in opioid-tolerant patients. The company said that

Elan has filed suit against Biogen Idec in Federal Court in New York. Elan is seeking declaratory and injunctive relief that certain aspects of its transaction with affiliates

Alnylam and Tekmira have reported that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles, for the

King Pharmaceuticals has submitted a briefing package to FDA addressing the issues raised in the Agency’s June 30 Complete Response Letter (CRL), related to the New Drug Application

Galapagos has completed its first-in-human trial of the novel candidate drug GLPG0259, for rheumatoid arthritis (RA). GLPG0259 is a novel mechanism-of-action inhibitor of the protein – kinase MAPKAPK5,

The Dow Chemical Company, along with the American Chemistry Council and other chemical manufacturers, has released guidance for the modernization of US chemical safety laws in Washington DC.